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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S285impacted mandibular third molar), and experienced moderate to severe
pain intensity 6 hours after surgery. Subjects received a single dose of
nano-formulated, lower dose diclofenac, indomethacin, or naproxen, an
active comparator (parent compound or celecoxib), or placebo. Safety and
tolerability were assessed by examining the treatment-emergent adverse
events (TEAE) for each treatment compared with placebo. The primary
efﬁcacy endpoints were sum of total pain relief (TOTPAR) 0 to 12 hours
(diclofenac and naproxen) and 0 to 8 hours (indomethacin.)
Results: Safety and tolerability for all nano-formulated NSAIDs and
comparator treatments, as determined by the number of subjects of 1
severe TEAE, were similar when compared with placebo. Overall, TEAEs
occurred less frequently for nano-formulated diclofenac (18 mg and 35
mg) than they did with celecoxib 400 mg. The proportion of subjects with
1 severe TEAE was 0% (0/49), 3.9% (2/51), 2.0% (1/51), and 7.8% (4/51) for
nano-formulated diclofenac 18 mg, 35 mg, celecoxib 400 mg, and placebo,
respectively. TEAEs occurred less frequently in nano-formulated indo-
methacin 20 mg and 40 mg compared with placebo. The proportion of
subjects with 1 severe TEAE was 1.0% (2/50), 1.0% (2/51), 5.9% (3/51), and
5.9% (3/51) for nano-formulated indomethacin 20 mg, 40 mg, celecoxib
400 mg, and placebo, respectively. For nano-formulated naproxen, TEAEs
occurred less frequently for both nano-formulated naproxen doses (200
mg and 400 mg) compared with placebo. The proportion of subjects with
1 severe TEAE was 2.0% (1/51), 0% (0/51), 2.0% (1/50), 2.0% (1/50), and 0%
(0/51) for nano-formulated naproxen 200 mg, 400 mg, standard naproxen
250 mg, 500 mg, and placebo, respectively.
ĂThe nano-formulated NSAIDs achieved the primary efﬁcacy endpoints by
exhibiting statistically signiﬁcant improvements (P<0.001) in TOTPAR-8 or
-12 compared with placebo. For nano-formulated diclofenac and nano-
formulated naproxen, TOTPAR values were numerically better than the
active comparators. However, these studies were not powered to assess
statistical differences.
Conclusions: Investigational, nano-formulated, lower dose, oral NSAIDs
demonstrated comparable safety and tolerability, as well as efﬁcacy, in an
established acute pain model. These Phase 2 data suggest that nano-
formulated diclofenac, indomethacin, and naproxen may offer efﬁcacy at
a lower dose and better tolerability and deserve further investigation in
Phase 3 clinical trials. The aforementioned results are in line with the FDA
directive to use the lowest effective NSAID dose.
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BASELINE AND LONGITUDINAL PATTERNS OF NSAID USE FOR
SYMPTOMATIC KNEE OSTEOARTHRITIS: THE OAI
C.B. Eaton 1, J.B. Driban 2, M.B. Roberts 3, K.L. Lapane 4, M. Nevitt 5,
T.E. McAlindon 2. 1Warren Alpert Med. Sch. of Brown Univ., Providence, RI,
USA; 2 Tufts Med. Ctr., Boston, MA, USA; 3Mem. Hosp. of Rhode Island,
Pawtucket, RI, USA; 4Virginia Commonwealth Univ., Richmond, VA, USA;
5Univ. of California at San Francisco, San Francisco, CA, USAPurpose:Pharmacokinetic studies andclinical trials demonstrate that regular
use of NSAIDs are needed for its anti-inﬂammatory properties to be effective
in the treatment of knee osteoarthritis. However regular use of NSAIDs are
associatedwith increased rates of GI toxicity and cardiovascular disease. Thus
the FDA issued black box warning labels regarding these risks and suggested
that doctors and patients use NSAIDS at the lowest possible dose and
frequency to achieve clinical beneﬁt. We were interested in describing the
range of use of NSAIDs in participants with symptomatic knee osteoarthritis
and predictors of its baseline use, changes in patterns of use over time.
Methods: NSAID use was determined based upon questionnaire regarding
self-report and medication inventory requiring participants to bring in all
their prescription bottles . NSAID use was divided into three categories:
non use, OTC or infrequent use, regular use. Polytomous regression anal-
ysis was performed to predict categories of use at baseline using backward
selection models.
Results: 1172 participants with symptomatic knee OA were indentiﬁed in
the OAI study at baseline. Non use of NSAIDS was found in 722 (61.6%), 356
(30.4%) infrequent use and 94(8%) regular use. Regular users were more
likely than none users to be obese (aOR¼1.80, 95% CI 1.13-2.88), have
worse SF-12 physical function scores (aOR¼ 0.97, 95% CI 0.95-0.99), and
trends for worse WOMAC pain (aOR¼ 1.03, 95%CI 0.97-1.11, higher rates of
a history of knee surgery (aOR¼1.55, 95%CI 0.99-2.41), and concomitant
CAM therapy(aOR¼1.42,95%CI 0.90-2.23). Infrequent NSAID users
compared to non users were more likely to have worse SF-12 mental
health scores (aOR¼0.98, 0.97-0.99), worse WOMAC pain scores
(aOR¼1.05, 95%CI 1.01-1.09),and more CAM therapy use (aOR¼1.32, 95% CI
1.01-1.74). Regular users only differed from infrequent users by obesity
status (aOR¼ 1.89, 95% CI 1.16-3.09). Patterns of use are shown in the ﬁgure
below. Over 48 months of follow-up, nearly 2/3 of non users stayed non
users, while only a 1/3 of infrequent users stayed infrequent users , and
only 25% of frequent users stayed frequent users.
Conclusions: Regular NSAID use for symptomatic knee OA is modest (<
10%) in this study and is associated with obesity, worse physical func-
tioning while infrequent use is associated with worse mental health, and
more CAM therapy. Over four years of follow-up non users remained
relatively constant while infrequent and frequent users changed cate-
gories. Understanding the reasons for lack of use of NSAIDS and changing
patterns may inform better patient centered outcomes research.
Ă
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A PROPRIETARY, NANO-FORMULATED, LOWER DOSE ORAL NAPROXEN
PROVIDES EFFECTIVE PAIN RELIEF
R. Altman 1, S. Daniels 2, G. Manvelian 3. 1UCLA Med. Ctr. RHU, Los Angeles,
CA, USA; 2 Premier Res. Group Limited, Clin. Res. Ctrs., Austin, TX, USA; 3 Iroko
Pharmaceuticals, Philadelphia, PA, USA
Purpose: Naproxen is commonly prescribed for the relief of musculo-
skeletal conditions including arthritis. Naproxen, like other NSAIDs, has
the potential for serious adverse events (AEs). NSAID AEs have demon-
strated to be dose-dependent. Our objective was to evaluate the analgesic
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S286efﬁcacy and safety of an investigational, proprietary, nano-formulated,
lower dose, oral naproxen formulated at 20% lower dose of standard
naproxen compared with placebo and standard naproxen in a validated
and standardized acute pain model.
Methods: This was a Phase 2, multicenter, randomized, single-dose, active-
and placebo-controlled trial. In total, 253 subjects whowere 18-50 years of
agewere enrolled following extraction of2 thirdmolars (1 ofwhichwas
a fully or partially impacted mandibular third molar) who experienced
moderate to severe pain (a score of 50 mm on a 100 mm Visual Analogue
Scale [VAS]) 6 hours after surgery). Subjects received a single dose of
nano-formulated, lower dose naproxen 200 mg or 400 mg, standard nap-
roxen 250mg or 500mg, or placebo. The primary efﬁcacy endpoint was the
sum of total pain relief (TOTPAR) over 0-12 hours (TOTPAR-12). TOTPAR-8,
time to onset of analgesia, and safety and tolerability were also assessed.
ĂResults: Overall, treatment-emergent AEs occurred in 53.9% (137/254) of
subjects. Treatment-related AEs occurred in 5.1% (13/254) of subjects and
were less frequent in subjects receiving nano-formulated naproxen (1%
combined for both nano-formulations) than standard naproxen (5%
combined for both standard formulations).
Conclusions: Nano-formulated, lower dose, oral naproxen demonstrated
good efﬁcacy, onset of action, and tolerability. The ability to utilize a lower
dose and maintain efﬁcacy could result in an improved tolerability and
safety proﬁle and is in line with the FDA directive to use the lowest
effective dose. Further investigation in Phase 3 trials is warranted.
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MULTIMODALITY IMAGING REVEALS NO SIGNIFICANT DIFFERENCES IN
BONE OR JOINT SPACE WIDTH BETWEEN STATIN USERS AND
NONUSERS: DATA FROM THE OSTEOARTHRITIS INITIATIVE
J.B. Driban 1, G.H. Lo 2, C.B. Eaton 3, K.L. Lapane 4, M. Nevitt 5, T.E.
McAlindon 1. 1 Tufts Med. Ctr., Boston, MA, USA; 2Michael E. DeBakey VA
Med. Ctr., Baylor Coll. of Med., Houston, TX, USA; 3Ctr. for Primary Care
and Prevention, Alpert Med. Sch. of Brown Univ., Pawtucket, RI, USA;
4Dept. of Epidemiology and Community Hlth., Virginia Commonwealth
Univ., Richmond, VA, USA; 5Dept. of Epidemiology and Biostatistics at the
Univ. of California, San Francisco, CA, USATable. Overview of Multiple Linear Regression Models and Estimates for Statin Users
Users Nonusers Overall Mod
n n R2
Baseline paBMD ratio 134 194 0.03
Baseline aTb.Sp (mm) 117 160 0.17
Baseline JSW250 (mm) 108 151 0.05
Change paBMD ratio 124 175 0.01
Change aTb.Sp (mm) 116 157 0.01
Change JSW250 (mm) 105 147 0.01
Multiple linear regression models included age, weight, Caucasian, male. paBMD ¼ peria
joint space width at x ¼ 0.250.Purpose: Based on in vitro and animal studies it has been hypothesized
that statins may ameliorate structural changes associated with osteoar-
thritis (OA). Among humans, statin users may have reduced knee OA
incidence/progression compared nonusers but these ﬁndings relied on
semi-quantitative radiographic outcomes. Therefore, we evaluated if
consistent long-term statin use was associated with quantitative structural
characteristics of knees with and without tibiofemoral OA using dual-
energy x-ray absorptiometry (DXA), high-resolution magnetic resonance
(MR) imaging, and radiographs.
Methods: The sample comprised a convenience sample of 592 partici-
pants in the Osteoarthritis Initiative (OAI) progression cohort who at the
30- or 36-month and 48-month OAI visits had 3-tesla MR imaging of the
right knee that included coronal 3D fast imaging with steady state
precession trabecular morphometry sequences and knee DXA scans.
Participants were excluded if they had missing medication inventory
form data at any annual OAI visit (baseline to 48-month follow-up).
Statin users were deﬁned as individuals who reported regularly using
statins at every annual OAI visit. Nonusers were deﬁned as individuals
who never reported statin use at an annual OAI visit. Trabecular
morphometry was assessed with a program with a modiﬁed algorithm
(calcDCN, University of California-San Francisco) to evaluate 4 apparent
peri-articular trabecular morphology measures in the central region of
the peri-articular medial tibia: bone volume fraction, trabecular number,
spacing (atb.sp), and thickness. Knee DXA scans were used to derive
a tibial peri-articular bone mineral density (paBMD) ratio (medial paBMD
divided by lateral paBMD). Location-speciﬁc joint space width (JSW, x ¼
0.250) was assessed at the 24-month and 48-month OAI visits. Longi-
tudinal change was calculated as follow-up minus baseline. JSW change
was determined over 24 months while paBMD and trabecular
morphometry change were based on 18- or 12- month change. Multiple
linear regression models were used to explore the association between
statin use and structural outcomes as well as change in structural
outcomes while controlling for age, body weight, sex, racial background
(Caucasian, not Caucasian). To reduce the number of models, only atb.sp
was analyzed among the trabecular morphometry outcomes since
previous analyses have indicated that atb.sp tends to be the most
responsive and it is derived from the other trabecular measures. Chi-
squares and independent sample t-tests were used to assess differences
in demographic and anthropometric data between statin users and
nonusers. A sensitivity analysis was performed that excluded participants
with a hip-knee-ankle angle < -2 degrees on full-limb radiograph (varus
alignment).
Results: Among 592 participants, 137 (23%) participants were statin users
and 196 (33%) participants were nonusers. Statin users and nonusers had
similar distributions of females (users ¼ 44%, nonusers ¼ 53%, p ¼ .12)
and right knees with no radiographic tibiofemoral OA (Kellgren-Lawrence
0 or 1; users ¼ 29%, nonusers ¼ 29%, p ¼ .96). More users (83%) were
Caucasian than nonusers (71%, p ¼ .01). Body weights were similar
among users (85  15 kg) and nonusers (86  16 kg, p ¼ .35) but users
(67  7 years) were older than nonusers (64  9 years, p < .01).
Consistent long-term statin use was not associated with baseline struc-
tural outcomes or changes in structural outcomes (see Table). A sensi-
tivity analysis that excluded individuals with varus alignment had similar
ﬁndings.
Conclusions: Consistent long-term statin use was not associatedwith JSW,
paBMD, or trabecular morphometry among knees with or without tibio-
femoral OA.el Parameter Estimate for User
(p value) Estimate Standard Error p value
(0.05) -0.016 (0.017) 0.35
(<0.01) 0.245 (0.141) 0.08
(0.02) 0.095 (0.211) 0.65
(0.60) 0.004 (0.007) 0.53
(0.69) 0.052 (0.094) 0.58
(0.65) -0.055 (0.105) 0.60
rticular bone mineral density, aTb.Sp ¼ apparent trabecular spacing, and JSW250 ¼
